BLRX News and Press, BioLineRx Ltd. From 06/16/22

BioLineRx (NASDAQ:BLRX) appointed Holly May as its chief commercial officer to bolster efforts for its investigational stem cell therapy for blood cancer. The Israeli company said that in the newly created role, which is based in the U.S., May will be responsible for commercial planning and l...

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer PR Newswire - Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 ca...

BioLineRx Ltd. (BLRX) Q1 2022 Earnings Conference Call May 11, 2022, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - CEO Mali Zeevi - CFO Conference Call Participants Mark Breidenbach - Oppenheimer John Vandermosten - Zacks Presentation Operator Ladies and...

biolinerx press release (NASDAQ:BLRX): Q1 GAAP EPS of -$0.02. Ended the first quarter on solid financial footing, with cash and cash equivalents of $50.6 million, sufficient to fund operations, as currently planned, into the first half of 2024. For further details see: biolinerx GAAP EP...

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire - On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consisten...

biolinerx (NASDAQ:BLRX) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.15 (-650.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward....

BioLineRx to Report First Quarter 2022 Results on May 11, 2022 PR Newswire Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 5, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-s...

Call Start: 10:00 Call End: 10:31 BioLineRx Ltd. (BLRX) Q4 2021 Earnings Conference Call March 16, 2022 10:00 ET CompanyParticipants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Abi Vai...

biolinerx press release (NASDAQ:BLRX): FY GAAP EPS of -$0.04 beats by $0.42. CEO comment: "With over $57 million in cash, we believe we are well financed to extract maximum value from Motixafortide in SCM while at the same time advancing our other pipeline programs." Upcoming Expected Milesto...

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highl...